Memantine Hydrochloride Perennial Pharma (Memantine Hydrochloride)

Memantine Hydrochloride is an NMDA‑receptor antagonist used in the management of Alzheimer’s disease and related cognitive decline.

• Moderate to severe Alzheimer’s disease: helps maintain cognition and daily functional abilities in affected adults.
• Alzheimer’s disease with behavioral symptoms: may reduce agitation and improve overall patient stability.
• Adjunct therapy in Alzheimer’s disease: can be combined with cholinesterase inhibitors to enhance therapeutic effect.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel with moderate affinity and rapid off‑rate, it blocks excessive calcium influx caused by pathological glutamate activation, thereby reducing excitotoxic neuronal injury while preserving normal synaptic transmission essential for learning and memory.

Memantine Hydrochloride may cause a range of adverse reactions. Most are mild and reversible, but serious events can occur.

Common Side Effects

• Dizziness: transient light‑headedness, especially at treatment initiation.
• Headache: mild to moderate intensity, often resolves with continued therapy.
• Constipation: reduced bowel movements, manageable with diet or laxatives.
• Confusion: occasional disorientation, typically improves over time.
• Fatigue: feeling unusually tired or low energy.
• Hypertension: modest increase in blood pressure in some patients.

Serious or Rare Side Effects

• Seizures: rare but may occur, particularly in patients with a seizure history.
• Cardiac arrhythmia: abnormal heart rhythms reported in isolated cases.
• Hepatic injury: elevated liver enzymes or hepatitis symptoms.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Suicidal ideation: emergent thoughts of self‑harm requiring immediate evaluation.
• Psychosis: new or worsening hallucinations or delusions.

When prescribing Memantine Hydrochloride, clinicians should consider several safety aspects.

• Renal impairment: adjust dose or monitor closely in patients with reduced kidney function.
• Hepatic impairment: use caution and monitor liver enzymes in patients with liver disease.
• History of seizures: evaluate risk and consider alternative therapy if seizures are uncontrolled.
• Concomitant NMDA antagonists: avoid combining with other NMDA‑blocking agents to prevent additive neurotoxicity.
• Elderly patients: start at low dose and titrate slowly to reduce adverse effects.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Memantine Hydrochloride can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase neurotoxicity.
• Ketamine: combined NMDA blockade can exacerbate central nervous system effects.
• Dextromethorphan: heightened risk of confusion and dizziness.
• High‑dose zinc supplements: may reduce memantine absorption.
• Strong CYP3A4 inducers (e.g., rifampin): may lower plasma concentrations.

Moderate Interactions (Monitor Closely)

• Cholinesterase inhibitors (donepezil, rivastigmine): monitor for synergistic cognitive effects.
• Antihypertensives: possible additive blood pressure lowering.
• CNS depressants (benzodiazepines, opioids): watch for increased sedation.
• Anticholinergic drugs: may worsen cognitive side effects.
• Diuretics: monitor electrolyte balance and renal function.